💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Bupropion Hydrobromide

CHEMBL1201735 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
320.6 g/mol
LogP
—
Phase
4

The hydrobromide salt of bupropion, formulated as an extended-release tablet specifically for the treatment of major depressive disorder and seasonal affective disorder. Like other bupropion formulations, it inhibits dopamine and norepinephrine reuptake. It has a lower risk of sexual side effects compared to serotonergic antidepressants.

Molekularmasse

320,6500 g/mol

TPSA

29,10 Ų

Therapeutische Bereiche

Major Depressive Disorder

Wirkmechanismus

Norepinephrine-dopamine reuptake inhibitor (NDRI).

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Norepinephrine-dopamine reuptake inhibitor (NDRI).

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C13H18ClNO.BrH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

                

                

                

                    
                    

                        
Molecular Formula

                        
C13H19BrClNO

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
Rotierbare Bindungen

                        
4

                    

                    
                    
                    

                        
Schwere Atome

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
The hydrobromide salt of bupropion, formulated as an extended-release tablet specifically for the treatment of major depressive disorder and seasonal affective disorder. Like other bupropion formulations, it inhibits dopamine and norepinephrine reuptake. It has a lower risk of sexual side effects compared to serotonergic antidepressants.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Norepinephrine-dopamine reuptake inhibitor (NDRI).

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Bupropion Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201735.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11984562.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.